Videos

Sal Patel, JD, partner at Schiff Hardin, LLP, explains how the Supreme Court's 2017 ruling in Sandoz v Amgen changed the biosimilars landscape.

Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he expects to see more settlements between drug manufacturers in the future.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses which therapeutic areas need biosimilars the most.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, addresses key differences between the US market and the EU market for biosimilars.

Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he is watching litigations concerning rheumatoid arthritis drugs closely.

Imron Aly, JD, partner at Schiff Hardin, LLP, explains how lessons learned from Hatch-Waxman proceedings can be applied to Biologics Price Competition and Innovation Act (BPCIA) litigation.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses the challenges that biosimilar developers face in getting their products to market.

Sheila Frame, vice president and head of biopharmaceuticals, North America, at Sandoz, discusses lessons learned from the launch of the company’s biosimilar filgrastim.

Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses what drives high drug costs in the United States.

Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses the burden of high-cost biologics for patients with rheumatic diseases.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses successes in drug patent challenges.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the link between drug patents and innovation.

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why patients with rheumatic diseases are at risk for thromboembolism.

Anne Bass, MD, rheumatologist at the Hospital for Special Surgery and professor of clinical medicine at Weill Cornell Medicine, explains why screening patients for tuberculosis before initiating biologic therapy is key.

Imron Aly, JD, partner at Schiff Hardin, LLP, explains how biosimilar developers can minimize uncertainty in patent litigation.

Imron Aly, JD, partner at Schiff Hardin, LLP, discusses key trends emerging in Biologics Price Competition and Innovation Act (BPCIA) litigation.

Speaking with the The Center for Biosimilars® the day before the Supreme Court of the United States ruled in Oil States Energy Services, LLC, v Greene’s Energy Group, LLC, Imron Aly, JD, partner at Schiff Hardin, LLP, explained the issues at stake in the case.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses the role that his group plays in patent opposition.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses how settlements can impact patient access to biosimilars.

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, a public interest team of attorneys and scientists who ensure that patents do not obstruct access to affordable medicines for patients in the United States and around the world, discusses transparency in drug pricing.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses value and patient co-payment assistance programs.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, explains what patients will need to feel comfortable with switching to a biosimilar.

Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, and Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discuss the value of biosimilars to the healthcare system.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses step therapy and its impact on patients.

Stephen Marmaras, director of policy and advocacy for the Global Healthy Living Foundation, discusses credible, patient-friendly resources that people with rheumatic diseases can access when they or their providers are considering a switch to a biosimilar.

Louis Tharp, cofounder and executive director of the Global Healthy Living Foundation, discusses lessons learned from international experience with biosimilar uptake.

Ray Bailey, RPh, Pharmacy Director at Florida Cancer Specialists, discusses the complexities of biosimilars.

Linda Frisk, PharmD, of Arizona Oncology, discusses biosimilars and cost savings.

Julianne Orr, outpatient oncology clinical pharmacist, Indiana University Health, explains that biosimilars remain a gray area for pharmacists.

Steven D’Amato, RPh, executive director and clinical pharmacy specialist at New England Cancer Specialists, explains the factors that he feels will impact adoption of biosimilars.